Validation of the Zevalin® Purification Process: A Case Study

Process Validationin Manufacturing of Biopharmaceuticals, Third edition

Volumn , Issue , 2012, Pages 455-490

  Conley, Lynn ^a   McPherson, John ^a   Thömmes, Jörg ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84979151055     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b12013-21     Document Type: Chapter

References (18)

1. International Conference on Harmonization (ICH). “Good Manufacturing Practice for Active Pharmaceutical Ingredients, Q7A, Step 4, " November 10, 2000.
2. U.S. Food and Drug Administration. “Guideline on General Principles of Process Validation, " May 1987.
3. U.S. Food and Drug Administration. “Manufacturing, Processing or Holding Active Pharmaceutical Ingredients, " March 1998.
4. Seely, R., M. Tomusiak, and R. Kuhn. In Biopharmaceutical Process Validation. Edited by G. Sofer and D. Zabriske. New York: Marcel Deker, 2000, 130.
5. Gardner, A., T. Smith, R. Gerber, and D. Zabriskie. “Worst Case Approach to Validating Operation Ranges.” In Validation of Bio-pharmaceuticals Manufacturing Processes, ACS Symp. Ser. No. 698. Edited by B. Kelly and A. Ramelmeir. Washington, DC: ACS Books, 69-79.
6. Smith, T., E. Wilson, R. Scott, J. Misczak, J. Bodek, and D. Zabriskie. “Establishment of Operating Ranges in a Purification Process for a Monoclonal Antibody.” In Validation of Biopharmaceuticals Manufacturing Processes, ACS Symp. Ser. No. 698. Edited by B. Kelly and A. Ramelmeir. Washington, DC: ACS Books, 80-92.
7. International Conference on Harmonization (ICH). “Guideline Q6A Step 4, Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, " March 1999.
8. International Conference on Harmonization (ICH). “Q5A Step 4, Consensus Guideline, Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, " (CPMP/ICH/295/95), 1995.
9. Darling, A. “Validation of Biopharmaceutical Purification Process for Viral Clearance Evaluation.” Mol. Biotechnol., May 2002, 57-83.
10. Center for Biologics Evaluation and Research. “Points to Consider in the Manufacturing and Testing of Monoclonal Antibody Products for Human Use.” Rockville, MD: US Food and Drug Administration, 1997.
11. World Health Organization. “Acceptability of Cell Substances for Production of Biologicals.” World Health Organization Tech. Report Ser. 747, 1987.
12. Griffiths, E. “WHO Expert Committee on Biological Standardization: Highlights of the Meeting of October 1996.” Biologicals 25 (1997): 359-362.
13. Sofer, G., and L. Hagel. Handbook of Process Chromatography: A Guide to Optimization Scale-Up and Validation. San Diego, CA: Academic Press, 1997, 159.
14. Gagnon, P. Purification Tools for Monoclonal Antibodies. Tucson, AZ: Validated Biosystems, 1996, 174-175.
15. “Technical Report No. 26, Sterilizing Filtration of Liquids.” PDA J. Pharm. Sci. Technol., 2008, 52 (suppl.).
16. Stone, T., V. Goel, and J. Loszcak. Methodology for Analysis of Filter Extractables: A Model Solvent Approach.” Pharm. Technol. 18 (1994): 116-130.
17. Reif, O., P. Solkner, and J. Rupp. “Analysis and Evaluation of Filter Cartridge Extractables for Validation in Pharmaceutical Downstream Processing.” Pharm. Technol. 50 (1996): 399-410.
18. Weitzmen, C. “The Use of Model Solvents for Evaluating Extractables from Filters Used to Process Pharmaceutical Products.” Pharm. Technol. 10 (1997): 72-99.